Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Jasper Therapeutics, Inc.JSPR · Entity 7588 | Director · CEO and President | February 06, 2026 | February 10, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Jasper Therapeutics, Inc.
Report date February 06, 2026 · Filed February 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.35 · Expires 2036-02-06 | Direct | 500,000 |
Reported balance
After 2026-02-06 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-02-06 · Grant · Acquired 500,000 · Balance 500,000 F1: 1/4th of the shares subject to the option shall vest on February 6, 2027, and 1/48th of the original number of shares subject to the option shall vest following each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive. |
Filing footnotes · ownership attribution and instrument terms
F1: 1/4th of the shares subject to the option shall vest on February 6, 2027, and 1/48th of the original number of shares subject to the option shall vest following each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 06, 2026 Filed Feb 10, 2026 16:00 UTC | Jasper Therapeutics, Inc. JSPR · Entity 7588 | GrantStock Option (right to buy) · Derivative | 500,000 | $0.00 Strike: $1.35 | $0.00 |
DisclosureSEC source: 0001213900-26-014244 · ownership.xml · derivative · entry 1 Mahal Jeetinder Singh · CIK 0001882877 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 500,000 Underlying: Voting Common Stock · 500,000 shares Expires 2036-02-06 F1 · derivative.exercise_date: 1/4th of the shares subject to the option shall vest on February 6, 2027, and 1/48th of the original number of shares subject to the option shall vest following each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive. Read SEC document |
| January 02, 2026 Filed Jan 5, 2026 19:30 UTC | Jasper Therapeutics, Inc. JSPR · Entity 7588 | GrantStock Option (right to buy) · Derivative | 90,000 | $0.00 Strike: $1.84 | $0.00 |
DisclosureSEC source: 0001213900-26-001383 · ownership.xml · derivative · entry 1 Mahal Jeetinder Singh · CIK 0001882877 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,000 Underlying: Voting Common Stock · 90,000 shares Expires 2036-01-02 F1 · derivative.exercise_date: 1/4th of the shares subject to the option shall vest on January 2, 2027, and 1/48th of the original number of shares subject to the option shall vest following each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive. Read SEC document |
| June 04, 2025 Filed Jun 6, 2025 06:27 UTC | Jasper Therapeutics, Inc. JSPR · Entity 7588 | GrantStock Option (right to buy) · Derivative | 90,000 | $0.00 Strike: $6.00 | $0.00 |
DisclosureSEC source: 0001213900-25-051726 · ownership.xml · derivative · entry 1 Mahal Jeetinder Singh · CIK 0001882877 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,000 Underlying: Voting Common Stock · 90,000 shares Expires 2035-06-04 F1 · derivative.exercise_date: 1/4th of the shares subject to the retention option shall vest on June 4, 2026 and 1/48th of the shares subject to the retention option shall vest following each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive. Read SEC document |
| February 13, 2025 Filed Feb 18, 2025 17:31 UTC | Jasper Therapeutics, Inc. JSPR · Entity 7588 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $6.20 | $0.00 |
DisclosureSEC source: 0001213900-25-014951 · ownership.xml · derivative · entry 1 Mahal Jeetinder Singh · CIK 0001882877 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Voting Common Stock · 50,000 shares Expires 2035-02-13 F1 · derivative.exercise_date: 1/4th of the shares subject to the option shall vest on February 13, 2026, and 1/48th of the original number of shares subject to the option shall vest following each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive. Read SEC document |
| December 12, 2024 Filed Dec 12, 2024 20:02 UTC | Jasper Therapeutics, Inc. JSPR · Entity 7588 | Exercise / conversionStock Option (right to buy) · Derivative | 900 | $0.00 Strike: $7.10 | $0.00 |
DisclosureSEC source: 0001213900-24-108551 · ownership.xml · derivative · entry 3 Mahal Jeetinder Singh · CIK 0001882877 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,772 Underlying: Voting Common Stock · 900 shares Expires 2030-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2023. F2 · derivative.exercise_date: 25% of the original number of shares subject to the option vested on December 12, 2020, and 1/48th of the original number of shares subject to the option vested monthly thereafter. Read SEC document |
| December 12, 2024 Filed Dec 12, 2024 20:02 UTC | Jasper Therapeutics, Inc. JSPR · Entity 7588 | SaleVoting Common Stock | 900 | $22.11 | $19,899.00 |
DisclosureSEC source: 0001213900-24-108551 · ownership.xml · nonDerivative · entry 2 Mahal Jeetinder Singh · CIK 0001882877 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,009 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2023. Read SEC document |
| December 12, 2024 Filed Dec 12, 2024 20:02 UTC | Jasper Therapeutics, Inc. JSPR · Entity 7588 | Exercise / conversionVoting Common Stock | 900 | $7.10 | $6,390.00 |
DisclosureSEC source: 0001213900-24-108551 · ownership.xml · nonDerivative · entry 1 Mahal Jeetinder Singh · CIK 0001882877 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,909 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2023. Read SEC document |
| September 12, 2024 Filed Sep 12, 2024 17:19 UTC | Jasper Therapeutics, Inc. JSPR · Entity 7588 | Exercise / conversionStock Option (right to buy) · Derivative | 900 | $0.00 Strike: $7.10 | $0.00 |
DisclosureSEC source: 0001213900-24-078214 · ownership.xml · derivative · entry 3 Mahal Jeetinder Singh · CIK 0001882877 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 14,672 Underlying: Voting Common Stock · 900 shares Expires 2030-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2023. F3 · derivative.exercise_date: 25% of the original number of shares subject to the option vested on December 12, 2020, and 1/48th of the original number of shares subject to the option vested monthly thereafter. Read SEC document |
| September 12, 2024 Filed Sep 12, 2024 17:19 UTC | Jasper Therapeutics, Inc. JSPR · Entity 7588 | SaleVoting Common Stock | 900 | $21.23 | $19,103.67 |
DisclosureSEC source: 0001213900-24-078214 · ownership.xml · nonDerivative · entry 2 Mahal Jeetinder Singh · CIK 0001882877 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,009 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2023. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.795 to $21.495, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased or sold at each separate price. Read SEC document |
| September 12, 2024 Filed Sep 12, 2024 17:19 UTC | Jasper Therapeutics, Inc. JSPR · Entity 7588 | Exercise / conversionVoting Common Stock | 900 | $7.10 | $6,390.00 |
DisclosureSEC source: 0001213900-24-078214 · ownership.xml · nonDerivative · entry 1 Mahal Jeetinder Singh · CIK 0001882877 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,909 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2023. Read SEC document |
| June 12, 2024 Filed Jun 12, 2024 21:40 UTC | Jasper Therapeutics, Inc. JSPR · Entity 7588 | Exercise / conversionStock Option (right to buy) · Derivative | 900 | $0.00 Strike: $7.10 | $0.00 |
DisclosureSEC source: 0001213900-24-052215 · ownership.xml · derivative · entry 3 Mahal Jeetinder Singh · CIK 0001882877 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,572 Underlying: Voting Common Stock · 900 shares Expires 2030-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2023. F3 · derivative.exercise_date: 25% of the original number of shares subject to the option vested on December 12, 2020, and 1/48th of the original number of shares subject to the option vested monthly thereafter. Read SEC document |
| June 12, 2024 Filed Jun 12, 2024 21:40 UTC | Jasper Therapeutics, Inc. JSPR · Entity 7588 | SaleVoting Common Stock | 900 | $24.16 | $21,739.50 |
DisclosureSEC source: 0001213900-24-052215 · ownership.xml · nonDerivative · entry 2 Mahal Jeetinder Singh · CIK 0001882877 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,009 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2023. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.975 to $24.555, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased or sold at each separate price. Read SEC document |
| June 12, 2024 Filed Jun 12, 2024 21:40 UTC | Jasper Therapeutics, Inc. JSPR · Entity 7588 | Exercise / conversionVoting Common Stock | 900 | $7.10 | $6,390.00 |
DisclosureSEC source: 0001213900-24-052215 · ownership.xml · nonDerivative · entry 1 Mahal Jeetinder Singh · CIK 0001882877 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,909 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2023. Read SEC document |
| March 12, 2024 Filed Mar 12, 2024 21:33 UTC | Jasper Therapeutics, Inc. JSPR · Entity 7588 | Exercise / conversionStock Option (right to buy) · Derivative | 900 | $0.00 Strike: $7.10 | $0.00 |
DisclosureSEC source: 0001213900-24-021961 · ownership.xml · derivative · entry 3 Mahal Jeetinder Singh · CIK 0001882877 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,472 Underlying: Voting Common Stock · 900 shares Expires 2030-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: The exercise price of the option and number of shares subject to the option were adjusted as a result of the Reverse Split, and numbers reported herein reflect the exercise price and number of shares subject to the option after the Reverse Split. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2023. F5 · derivative.exercise_date: 25% of the original number of shares subject to the option vested on December 12, 2020, and 1/48th of the original number of shares subject to the option vested monthly thereafter. F4 · balance_after: The exercise price of the option and number of shares subject to the option were adjusted as a result of the Reverse Split, and numbers reported herein reflect the exercise price and number of shares subject to the option after the Reverse Split. Read SEC document |
| March 12, 2024 Filed Mar 12, 2024 21:33 UTC | Jasper Therapeutics, Inc. JSPR · Entity 7588 | SaleVoting Common Stock | 900 | $26.44 | $23,792.22 |
DisclosureSEC source: 0001213900-24-021961 · ownership.xml · nonDerivative · entry 2 Mahal Jeetinder Singh · CIK 0001882877 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,009 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2023. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.14 to $26.79, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased or sold at each separate price. Read SEC document |
| March 12, 2024 Filed Mar 12, 2024 21:33 UTC | Jasper Therapeutics, Inc. JSPR · Entity 7588 | Exercise / conversionVoting Common Stock | 900 | $7.10 | $6,390.00 |
DisclosureSEC source: 0001213900-24-021961 · ownership.xml · nonDerivative · entry 1 Mahal Jeetinder Singh · CIK 0001882877 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,909 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2023. F2 · balance_after: Effective on January 4, 2024, the Issuer conducted a reverse stock split of its voting common stock at a ratio of 1-for-10 (the "Reverse Split"). The number of shares reported herein reflects the number of shares after the Reverse Split. Read SEC document |
| February 15, 2024 Filed Feb 20, 2024 19:31 UTC | Jasper Therapeutics, Inc. JSPR · Entity 7588 | GrantStock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $17.95 | $0.00 |
DisclosureSEC source: 0001213900-24-015462 · ownership.xml · derivative · entry 1 Mahal Jeetinder Singh · CIK 0001882877 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Voting Common Stock · 40,000 shares Expires 2034-02-15 F1 · derivative.exercise_date: 1/4th of the shares subject to the option shall vest on February 15, 2025, and 1/48th of the shares subject to the option shall vest following each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive. Read SEC document |
| October 12, 2023 Filed Oct 13, 2023 18:58 UTC | Jasper Therapeutics, Inc. JSPR · Entity 7588 | Tax withholdingVoting Common Stock | 37,126 | $0.85 | $31,557.10 |
DisclosureSEC source: 0001013762-23-003903 · ownership.xml · nonDerivative · entry 1 Mahal Jeetinder Singh · CIK 0001882877 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 250,097 F1 · shares: These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares of the Issuer's common stock upon the vesting of restricted stock units. Read SEC document |
| June 13, 2023 Filed Jun 13, 2023 20:54 UTC | Jasper Therapeutics, Inc. JSPR · Entity 7588 | Exercise / conversionStock Option (right to buy) · Derivative | 9,000 | $0.00 Strike: $0.71 | $0.00 |
DisclosureSEC source: 0001213900-23-048683 · ownership.xml · derivative · entry 3 Mahal Jeetinder Singh · CIK 0001882877 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 173,713 Underlying: Voting Common Stock · 9,000 shares Expires 2030-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2023. F3 · derivative.exercise_date: 25% of the original number of shares subject to the option vested on December 12, 2020, and 1/48th of the original number of shares have vested and shall vest monthly thereafter, subject to the Reporting Person's continued service to the Issuer through each such vesting date. Read SEC document |
| June 13, 2023 Filed Jun 13, 2023 20:54 UTC | Jasper Therapeutics, Inc. JSPR · Entity 7588 | SaleVoting Common Stock | 9,000 | $1.66 | $14,914.80 |
DisclosureSEC source: 0001213900-23-048683 · ownership.xml · nonDerivative · entry 2 Mahal Jeetinder Singh · CIK 0001882877 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 287,223 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2023. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.62 to $1.69, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased or sold at each separate price. Read SEC document |
| June 13, 2023 Filed Jun 13, 2023 20:54 UTC | Jasper Therapeutics, Inc. JSPR · Entity 7588 | Exercise / conversionVoting Common Stock | 9,000 | $0.71 | $6,390.00 |
DisclosureSEC source: 0001213900-23-048683 · ownership.xml · nonDerivative · entry 1 Mahal Jeetinder Singh · CIK 0001882877 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 296,223 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2023. Read SEC document |
| April 12, 2023 Filed Apr 14, 2023 16:16 UTC | Jasper Therapeutics, Inc. JSPR · Entity 7588 | Tax withholdingVoting Common Stock | 37,126 | $1.46 | $54,203.96 |
DisclosureSEC source: 0001213900-23-029893 · ownership.xml · nonDerivative · entry 1 Mahal Jeetinder Singh · CIK 0001882877 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 287,223 F1 · shares: These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares of the Issuer's common stock upon the vesting of restricted stock units. Read SEC document |
| March 17, 2023 Filed Mar 20, 2023 18:00 UTC | Jasper Therapeutics, Inc. JSPR · Entity 7588 | GrantStock Option (right to buy) · Derivative | 350,000 | $0.00 Strike: $1.87 | $0.00 |
DisclosureSEC source: 0001213900-23-021494 · marketforms-60959.xml · derivative · entry 1 Mahal Jeetinder Singh · CIK 0001882877 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 350,000 Underlying: Voting Common Stock · 350,000 shares Expires 2033-03-17 F1 · derivative.exercise_date: 1/4th of the shares subject to the option shall vest on March 3, 2024, and 1/48th of the shares subject to the option shall vest following each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive. Read SEC document |
| October 12, 2022 Filed Oct 13, 2022 20:02 UTC | Jasper Therapeutics, Inc. JSPR · Entity 7588 | GrantVoting Common Stock | 214,722 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-22-063941 · ownership.xml · nonDerivative · entry 1 Mahal Jeetinder Singh · CIK 0001882877 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 324,349 F1 · shares: The reported securities are represented by restricted stock units, 1/2 of which shall vest on each of April 12, 2023 and October 12, 2023, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive. Read SEC document |
| April 07, 2022 Filed Apr 8, 2022 16:01 UTC | Jasper Therapeutics, Inc. JSPR · Entity 7588 | GrantStock Option (right to buy) · Derivative | 48,441 | $0.00 Strike: $3.12 | $0.00 |
DisclosureSEC source: 0001213900-22-018928 · ownership.xml · derivative · entry 1 Mahal Jeetinder Singh · CIK 0001882877 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,441 Underlying: Voting Common Stock · 48,441 shares Expires 2032-04-07 F1 · derivative.exercise_date: 1/4th of the shares subject to the option shall vest on March 21, 2023, and 1/48th of the shares subject to the option shall vest following each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive. Read SEC document |
| March 21, 2022 Filed Mar 23, 2022 18:02 UTC | Jasper Therapeutics, Inc. JSPR · Entity 7588 | GrantStock Option (right to buy) · Derivative | 87,272 | $0.00 Strike: $3.54 | $0.00 |
DisclosureSEC source: 0001213900-22-014565 · ownership.xml · derivative · entry 2 Mahal Jeetinder Singh · CIK 0001882877 · COO,CFO and CS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,272 Underlying: Voting Common Stock · 87,272 shares Expires 2032-03-21 F2 · derivative.exercise_date: 1/4th of the shares subject to the option shall vest on March 21, 2023, and 1/48th of the shares subject to the option shall vest following each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive. Read SEC document |
| March 21, 2022 Filed Mar 23, 2022 18:02 UTC | Jasper Therapeutics, Inc. JSPR · Entity 7588 | GrantStock Option (right to buy) · Derivative | 7,500 | $0.00 Strike: $3.54 | $0.00 |
DisclosureSEC source: 0001213900-22-014565 · ownership.xml · derivative · entry 1 Mahal Jeetinder Singh · CIK 0001882877 · COO,CFO and CS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Voting Common Stock · 7,500 shares Expires 2032-03-21 F1 · derivative.exercise_date: 1/4th of the shares subject to the option shall vest on December 7, 2022, and 1/48th of the shares subject to the option shall vest following each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.